Quebec To List Enoxaparin Biosimilar As Valeo Pharma Prepares Launch
Canadian Firm Plans Launch During First Half Of 2020
Executive Summary
Canada’s Valeo Pharma says it intends to pursue discussions for the inclusion of its Redesca enoxaparin biosimilar on all other provincial formularies, after being backed for listing on the Quebec public health plan.
You may also be interested in...
Sandoz Canada Joins Humira Biosimilar Race With Hyrimoz Approval
Sandoz Canada is looking to roll out its biosimilar to AbbVie’s Humira early in the new year following approval from Health Canada, with multiple other adalimumab candidates also reportedly approved.
Valeo Pharma To Launch Enoxaparin In Canada Early Next Year
Canadian firm Valeo Pharma is looking to make a splash with enoxaparin biosimilars, Redesca and Redesca HP, following approval from Health Canada.
Sandoz Canada Aims For 10 Biosimilar Launches In Next Decade
Speaking with Generics Bulletin as Sandoz Canada unveiled its landmark public education campaign, The Biosimilars Generation, Karine Matteau, the company’s biosimilars leader, talked about how it plans to remain a leader in the biosimilars field as well as the company’s response to the COVID-19 pandemic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: